Cargando…

ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation

Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those with activating epidermal growth factor receptor (EGFR) mutations. Elucidation of the mechanisms underlying EGFR-mediated tumor imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaozheng, Gao, Aiqin, Zhang, Fang, Yang, Zijiang, Wang, Shuyun, Fang, Yuying, Li, Juan, Wang, Jingnan, Shi, Wenjing, Wang, Linlin, Zheng, Yan, Sun, Yuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847666/ https://www.ncbi.nlm.nih.gov/pubmed/33537094 http://dx.doi.org/10.7150/thno.52435

Ejemplares similares

Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes
por: Li, Qing, et al.
Publicado: (2020)

ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression
por: Yang, Zijiang, et al.
Publicado: (2021)

Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
por: Gao, Aiqin, et al.
Publicado: (2021)

Tumor‐derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer
por: Shi, Wenjing, et al.
Publicado: (2022)

Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance
por: ZHANG, YI, et al.
Publicado: (2012)

PD‐L1/p‐STAT3 promotes the progression of NSCLC cells by regulating TAM polarization
por: Zhang, Rui, et al.
Publicado: (2022)

Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs
por: Gok Yavuz, Betul, et al.
Publicado: (2019)

Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
por: Tian, Yuan, et al.
Publicado: (2020)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer
por: Chen, Qiong-Yuan, et al.
Publicado: (2021)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
por: Schwich, Esther, et al.
Publicado: (2020)

Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)
por: Li, Yue, et al.
Publicado: (2021)

The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection
por: Brown, Damien P, et al.
Publicado: (2009)

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
por: Peters, Solange, et al.
Publicado: (2022)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Hypoxia‐related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD‐L1 squamous and adenocarcinoma NSCLC
por: Zhao, Fang, et al.
Publicado: (2021)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Air sampling for detection of infectious laryngotracheitis (ILT) in commercial poultry flocks
por: Brown, Lauren, et al.
Publicado: (2020)

HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges
por: Lin, Aifen, et al.
Publicado: (2021)

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
por: Hiltbrunner, Stefanie, et al.
Publicado: (2023)

Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment
por: Yang, Wenjie, et al.
Publicado: (2020)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression
por: Wang, Min, et al.
Publicado: (2021)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

Downregulation of Immunoglobulin-Like Transcript-4 (ILT4) in Patients with Psoriatic Arthritis
por: Bergamini, Alberto, et al.
Publicado: (2014)

The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells
por: Paavola, Kevin J., et al.
Publicado: (2021)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images
por: Wang, Chengdi, et al.
Publicado: (2022)

TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
por: Peeters, Marlies J. W., et al.
Publicado: (2019)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway
por: Lian, Guanghui, et al.
Publicado: (2019)

ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation
por: Monypenny, James, et al.
Publicado: (2018)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
por: Yeboah, Muchaala, et al.
Publicado: (2020)

Crystal structure of LIR-2 (ILT4) at 1.8 Å: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18
por: Willcox, Benjamin E, et al.
Publicado: (2002)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4r7rusnh5fk9f58jqavdtmfrt